Preclinical Safety Assessment of the 5-HT2A Receptor Agonist PET Radioligand [11C]Cimbi-36

[1] Gonzalez-Maeso J(2007)Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior Neuron 53 439-452

[2] Weisstaub NV(2001)Multiple conformations of native and recombinant human 5-hydroxytryptamine(2a) receptors are labeled by agonists and discriminated by antagonists Mol Pharmacol 60 690-699

[3] Zhou M(2010)Measuring endogenous 5-HT release by emission tomography: promises and pitfalls J Cereb Blood Flow Metab 30 1682-1706

[4] Lopez-Gimenez JF(2005)Measurement of the proportion of D2 receptors configured in state of high affinity for agonists in vivo: a positron emission tomography study using [ J Pharmacol Exp Ther 315 80-90

[5] Villazon M(2010)C]N-propyl-norapomorphine and [ J Pharmacol Exp Ther 333 533-539

[6] Brea J(2010)C]raclopride in baboons Curr Top Behav Neurosci 3 219-245

[7] Paterson LM(2012)A comparative evaluation of the dopamine D(2/3) agonist radiotracer [ J Cereb Blood Flow Metab 32 685-695

[8] Tyacke RJ(2012)C](−)-N-propyl-norapomorphine and antagonist [ Synapse 66 880-884

[9] Nutt DJ(2011)C]raclopride to measure amphetamine-induced dopamine release in the human striatum Synapse 65 1119-1127

[10] Narendran R(2010)Imaging neurotransmitter release by drugs of abuse J Nucl Med 51 1763-1770

[1] Gonzalez-Maeso J(2007)Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior Neuron 53 439-452

[2] Weisstaub NV(2001)Multiple conformations of native and recombinant human 5-hydroxytryptamine(2a) receptors are labeled by agonists and discriminated by antagonists Mol Pharmacol 60 690-699

[3] Zhou M(2010)Measuring endogenous 5-HT release by emission tomography: promises and pitfalls J Cereb Blood Flow Metab 30 1682-1706

[4] Lopez-Gimenez JF(2005)Measurement of the proportion of D2 receptors configured in state of high affinity for agonists in vivo: a positron emission tomography study using [ J Pharmacol Exp Ther 315 80-90

[5] Villazon M(2010)C]N-propyl-norapomorphine and [ J Pharmacol Exp Ther 333 533-539

[6] Brea J(2010)C]raclopride in baboons Curr Top Behav Neurosci 3 219-245

[7] Paterson LM(2012)A comparative evaluation of the dopamine D(2/3) agonist radiotracer [ J Cereb Blood Flow Metab 32 685-695

[8] Tyacke RJ(2012)C](−)-N-propyl-norapomorphine and antagonist [ Synapse 66 880-884

[9] Nutt DJ(2011)C]raclopride to measure amphetamine-induced dopamine release in the human striatum Synapse 65 1119-1127

[10] Narendran R(2010)Imaging neurotransmitter release by drugs of abuse J Nucl Med 51 1763-1770